Adjuvant Innovation — CpG 7909
The use of the CpG 7909 adjuvant in 2026 represents a milestone in immunology. This adjuvant works by mimicking bacterial DNA, which "tricks" the immune system into a state of high alert (activating Toll-like receptor 9).
This technology is the reason Cyfendus™ can achieve in two doses what BioThrax® takes three to achieve. It essentially "supercharges" the B-cells to produce antibodies against the anthrax Protective Antigen much faster, which is the difference between life and death in a biowarfare or terrorism scenario where the incubation period of the disease is short.
2 Views